Disparate adjuvant properties among three formulations of " alum"

Vaccine

Volumn 31, Issue 4, 2013, Pages 653-660

  Cain, Derek W ^a   Sanders, Sergio E ^a   Cunningham, Michael M ^a   Kelsoe, Garnett ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Alum; Antibody; Inflammation

Indexed keywords

(4 HYDROXY 3 NITROPHENYL)ACETYL CHICKEN GAMMA GLOBULIN; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; CYTOKINE; IMJECT; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; FEMALE; HAPTEN CARRIER COMPLEX; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLAMMATORY CELL; MOUSE; NONHUMAN; PLASMA CELL; PRECIPITATION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES; ANTIGENS; CYTOKINES; FEMALE; HUMANS; IMMUNIZATION; INFLAMMATION; MICE; MICE, INBRED C57BL;

EID: 84871933837     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.044     Document Type: Article

References (44)

1. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010, 28(Suppl. 3):C25-C36.
2. Vogel F.R., Powell M.F. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 1995, 6:141-228.
3. Shirodkar S., Hutchinson R.L., Perry D.L., White J.L., Hem S.L. Aluminum compounds used as adjuvants in vaccines. Pharm Res 1990, 7(12):1282-1288.
4. Edelman R. Vaccine adjuvants. Rev Infect Dis 1980, 2(3):370-383.
5. Krishnan L., Dicaire C.J., Patel G.B., Sprott G.D. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun 2000, 68(1):54-63.
6. Wilmar A., Lonez C., Vermeersch M., Andrianne M., Perez-Morga D., Ruysschaert J.M., et al. The cationic lipid: diC14 amidine, extends the adjuvant properties of aluminum salts through a TLR-4- and caspase-1-independent mechanism. Vaccine 2012, 30(2):414-424.
7. Yip H.C., Karulin A.Y., Tary-Lehmann M., Hesse M.D., Radeke H., Heeger P.S., et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 1999, 162(7):3942-3949.
8. Gottwein J.M., Blanchard T.G., Targoni O.S., Eisenberg J.C., Zagorski B.M., Redline R.W., et al. Protective anti-helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis 2001, 184(3):308-314.
9. Ogunniyi A.D., Folland R.L., Briles D.E., Hollingshead S.K., Paton J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 2000, 68(5):3028-3033.
10. Rao K.V., He Y.X., Kalyanasundaram R. Expression of a 28-kilodalton glutathione S-transferase antigen of Schistosoma mansoni on the surface of filamentous phages and evaluation of its vaccine potential. Clin Diagn Lab Immunol 2003, 10(4):536-541.
11. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
12. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314(5807):1936-1938.
13. Kool M., Petrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting Edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181(6):3755-3759.
14. Li H., Nookala S., Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1 beta and IL-18 release. J Immunol 2007, 178(8):5271-5276.
15. Hem S.L., Johnston C.T., HogenEsch H. Imject alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine 2007, 25(27):4985-4986.
16. Exley C., Siesjo P., Eriksson H. The immunobiology of aluminium adjuvants: how do they really work?. Trends Immunol 2010, 31(3):103-109.
17. Exley C. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes. Vaccine 2012, 30(12):2042.
18. Imanishi T., Makela O. Strain differences in the fine specificity of mouse anti-hapten antibodies. Eur J Immunol 1973, 3(6):323-330.
19. Tesch H., Takemori T., Rajewsky K. The immune response against anti-idiotope antibodies II. The induction of antibodies bearing the target idiotope (Ab3 beta) depends on the frequency of the corresponding B cells. Eur J Immunol 1983, 13(9):726-732.
20. Kuraoka M., Liao D., Yang K., Allgood S.D., Levesque M.C., Kelsoe G., et al. Activation-induced cytidine deaminase expression and activity in the absence of germinal centers: insights into hyper-IgM syndrome. J Immunol 2009, 183(5):3237-3248.
21. Takahashi Y., Dutta P.R., Cerasoli D.M., Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J Exp Med 1998, 187(6):885-895.
22. Takemori T., Rajewsky K. Lambda chain expression at different stages of ontogeny in C57 BL/6: BALB/c and SJL mice. Eur J Immunol 1981, 11(8):618-625.
23. Cain D.W., Snowden P.B., Sempowski G.D., Kelsoe G. Inflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism. PLoS ONE 2011, 6(5):e19957.
24. Stewart-Tull D.E.S. Recommendations for the assessment of adjuvants (immunopotentiators). Immunological adjuvants and vaccines 1989, Plenum, New York, p. 213-26. G. Greogoriadis, A.C. Allison, G. Poste (Eds.).
25. Gupta R.K., Rost B.E. Aluminum compounds as vaccine adjuvants. Methods in molecular medicine 2000, vol. 42:25. Humana Press, Totowa, NJ.
26. Jacob J., Kassir R., Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J Exp Med 1991, 173(5):1165-1175.
27. Jacob J., Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers. J Exp Med 1992, 176(3):679-687.
28. Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011, 17(8):996-1002.
29. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.
30. McKee A.S., Munks M.W., MacLeod M.K., Fleenor C.J., Van Rooijen N., Kappler J.W., et al. Alum induces innate immune responses through macrophage and mast cell sensors: but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183(7):4403-4414.
31. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol 1995, 6:229-248.
32. Hem S.L., White J.L. Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol 1995, 6:249-276.
33. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32(3):155-172.
34. Marrack P., Mckee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9(4):287-293.
35. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9(8):847-856.
36. Ueda Y., Cain D.W., Kuraoka M., Kondo M., Kelsoe G. IL-1R type I-dependent hemopoietic stem cell proliferation is necessary for inflammatory granulopoiesis and reactive neutrophilia. J Immunol 2009, 182(10):6477-6484.
37. Wang Y., Rahman D., Lehner T. A comparative study of stress-mediated immunological functions with the adjuvanticity of alum. J Biol Chem 2012, 287(21):17152-17160.
38. Kuroda E., Ishii K.J., Uematsu S., Ohata K., Coban C., Akira S., et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011, 34(4):514-526.
39. Glenny A.T., Buttle G.A.H., Stevens M.F. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. J Pathol Bacteriol 1931, 34(2):267-275.
40. Aprile M.A., Wardlaw A.C. Aluminum compounds as adjuvants for vaccine and toxoids in man: a review. Can J Pub Health 1966, 57:343-354.
41. al-Shakhshir R., Regnier F., White J.L., Hem S.L. Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants. Vaccine 1994, 12(5):472-474.
42. Hem S.L., White J.L. Characterization of aluminum hydroxide for use as an adjuvant in parenteral vaccines. J Parenter Sci Technol 1984, 38(1):2-10.
43. Masood H., White J.L., Hem S.L. Relationship between protein adsorptive capacity and the X-ray diffraction pattern of aluminium hydroxide adjuvants. Vaccine 1994, 12(2):187-189.
44. Seeber S.J., White J.L., Hem S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1991, 9(3):201-203.